BioWorld

July 31, 2003

ILEX Raises $93.5M In Secondary Public Offering Of Common Stock

ILEX Oncology Inc. gained gross proceeds of $93.5 million through the sale of 5.5 million common shares priced at $17 apiece. (BioWorld Today) Read More

If Passed, BIOFIX Would Fix Broken Tax Code For Biotechs

The Six-Country WHO Network Hands Down Its Final Verdict: Coronavirus Is Behind SARS

BioAxone Making Progress In Spinal Cord Injuries, Cancer

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Feb. 12, 2025.

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

News in brief

BioWorld Asia

BioWorld Asia briefs for Feb. 10, 2026